Sanofi SA (SNY) has released an update.
Sanofi SA announced promising Phase 2b trial results for amlitelimab, showing sustained improvements in atopic dermatitis symptoms for 28 weeks, even after ceasing treatment. The medication was well-tolerated with no new safety issues, supporting the potential for a quarterly dosing regimen. These findings, presented at the AAD 2024 Conference, highlight amlitelimab as a key asset in Sanofi’s robust immunology pipeline.
For further insights into SNY stock, check out TipRanks’ Stock Analysis page.
